Showcasing Women Leaders in Life Sciences: A panel discussion and networking event
Propel Careers along with careinnovators and Gene Network Sciences are proud to host a panel discussion and networking event intended to showcase women leaders in life sciences. The event will provide a platform to discuss their experiences, lessons learned, and advice on how they have successfully led their teams and companies. Join us for an evening of networking with industry professionals, entrepreneurs, and the future leaders of our industry.
Date: October 6, 2010 Time: 5:30 - 8:30pm Location: Bingham McCutchen LLP, 1 Federal Street, Boston MA 02110
Registration Details: http://womenlifescienceleaders.eventbrite.com/
If you are a MA-based student interested in attending this event, financial assistance is available through the Stay in MA program. Please visit http://www.stayinma.com/home
Agenda: 5:30pm-6:00pm – Registration and Open Networking 6:00pm-6:15pm – Introductions and Overview Propel Careers, careinnovators, GNS
6:15-6:30 – Discussion of the importance of Women Leaders
6:30 pm-7:30pm – Panel Discussion on Women Life Sciences Leaders Moderator: Laurie Halloran, CEO and Managing Partner, Halloran Consulting Group; Panelist: Ellen Baron, Ph.D., Partner, Oxford Bioscience Partners; Panelist: Lynda Chin, MD, Professor of Dermatology at the Harvard Medical School and co-Founder of Aveo Pharmaceuticals and Metamark Genetic; Panelist: Diane K. Jorkasky, M.D., Chief Medical Officer & SVP, Head of Development, Aileron Therapeutics, Inc.
7:30pm-8:30pm – Open Networking
Moderator and Panelists Biographies:
Laurie Halloran, CEO and Managing Partner, Halloran Consulting Group. Laurie founded Halloran Consulting Group in 1998. With over 20 years of experience in clinical affairs management with contract research organizations and biotechnology companies, Laurie is recognized as an industry expert in improving the organizational effectiveness of clinical research programs with a specialty in gap analysis and strategic planning. Laurie has executed over 25 clinical trials from Phase I to Phase III for both emerging and established companies and has managed operational budgets of up to $24 MM. Prior to founding Halloran Consulting Group, Laurie spent 10 years at PAREXEL International where she developed worldwide training capabilities with the clinical operations group. She has also established clinical operations at OXiGENE and Antigenics. She is an adjunct professor at Boston University Medical School. Laurie earned a B.S. in nursing from Russell Sage College and a M.S. in management from Leslie University. She is also a Prosci certified change management consultant. Laurie was recently recognized by PharmaVOICE as One of the 100 Most Inspiring People in the Life-Sciences Industry
Dr. Chin is a Professor of Dermatology at the Harvard Medical School and co-Founder of Aveo Pharmaceuticals and Metamark Genetic. Dr. Chin is a Professor of Dermatology at the Harvard Medical School and Department of Medical Oncology at Dana-Farber Cancer Institute and an Associate Member of the Broad Institute. At Dana-Farber and Harvard, Dr. Chin is the Scientific Director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute, and co-leads the Dana-Farber / Harvard Cancer Center's Melanoma Program and the Harvard Skin SPORE. At the Broad Institute, Dr. Chin is PI of the TCGA Genome Data Analysis Center. Dr. Chin co-founded AVEO Pharmaceuticals in 2002, a cancer biotechnology company that emphasizes cancer biology. Most recently, Dr. Chin also founded Metamark Genetic, a cancer diagnostic company that will develop function-based prognostic determinants that can guide customized management of early-staged cancer patients. Dr. Chin has made multiple scientific discoveries spanning the fields of transcription, mouse models of human cancer, and oncogenomics. She co-discovered Sin3 and established a role for Sin3 as a scaffold for histone deacetylase and N-CoR, both key modulators of chromatin and basal transcription. Her studies in the telomerase-deficient mice established telomere-based crisis as a key mutational process in the development of cancer, a process that is highly dependent upon the status of DNA damage checkpoints. More recently, Dr. Chin has focused on mining and translating complex multi-dimensional genomic data through comparative oncogenomics of mouse and human cancers and integration with functional genomics to identify novel cancer targets and diagnostic biomarkers. Dr. Chin is actively involved in The Cancer Genes Atlas (TCGA) Project, serving on its Executive Subcommittee and as chairs of the GBM and Melanoma Disease Working Groups that interface the genomic science within TCGA with basic and translational biology in the broader community. She is also a member of the Scientific Steering Committee of the International Cancer Genome Consortium. Dr. Chin received her M.D. from the Albert Einstein College of Medicine in 1993. She is a board-certified dermatologist and conducted her clinical and scientific training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine where she served as Chief Resident of Dermatology.
Ellen Baron, Ph.D., Partner, Oxford Bioscience Partners. Dr. Baron joined Oxford Bioscience Partners in 2003 and is currently is a Partner at the firm. She has over 20 years of operating and investment expertise in the pharmaceutical and biotechnology industry and is focused on all areas of healthcare investing, principally in biotherapeutics. Her current investments include BrainCells Inc (platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, Claros Diagnostics (diagnostic system delivering quantitative laboratory blood test results with ease-of-use for the point-of-care (POC), Tragara Pharmaceuticals (cancer clinical and commercial development),and VaxInnate Corporation (recombinant vaccine technology for pandemic and seasonal influenza). Dr. Baron acts as a Board Observer to Radius (drug therapies for osteoporosis and women's health) and acted as a board observer to Critical Therapeutics prior to its public listing. Prior to joining Oxford, Dr. Baron was Senior Vice President of Business Development at Human Genome Sciences, Inc. Prior to Human Genome Sciences, Dr. Baron spent 20 years at Schering-Plough Corporation in both Research and Development and Business Development. Dr. Baron received her B.A. from Goucher College, her Ph.D. in Microbiology from Georgetown University School of Medicine and was a post-doctoral at the Public Health Research Institute in New York.
Diane K. Jorkasky, M.D., Chief Medical Officer & SVP, Head of Development, Aileron Therapeutics, Inc. Dr. Diane Jorkasky is a 23 year veteran of the pharmaceutical industry with experience in Phase 1 through Phase 4. She is currently SVP, head of Development and Chief Medical Officer at Aileron Therapeutics in Cambridge, Massachusetts, where she is involved in the development of stapled peptides. Prior to this appointment she had been Vice President of Global Clinical Research Operations, its clinical research units, and leader of the Operational Excellence Board for Development at the Pfizer Global Research and Development New London, Connecticut. Dr. Jorkasky also established the Pfizer alliance in PET imaging with Yale Medical School, which, after its 7th year, had produced 66 peer reviewed publications and 10 critical decision studies for Pfizer. She is particularly interested in ensuring scientific strategy is realized through innovative application of technology to the operations. Dr Jorkasky is a member of the Connecticut Academy of Science and Technology. She has been recognized by the Connecticut Women's Hall of Fame for her scientific leadership and mentoring of young women and the Connecticut Council on Technology for her work in driving the technological improvements in the clinical research units. Dr. Jorkasky is board certified in internal medicine, nephrology and clinical pharmacology. She is on the faculties of Yale, Penn and Uniformed Service of Health Sciences Medical Schools. She has published on over 100 peer review articles. Most recently Dr. Jorkasky was selected to be a Woodrow Wilson visiting fellow.
About the organizers:
Propel Careers is a relationship driven search organization focused on providing companies access to top talent for full time, project-based, and internship opportunities. We also seek to cultivate current and future leaders in the life sciences through career development, networking, and mentorship. We believe in the mission of companies working to improve medicine and health care, and we operate with the intention of making our clients stronger, more competitive, and more successful for being a part of the Propel Network. We view our work with each client as a partnership and we look forward to seeing the results we deliver. To learn more, visit https://www.propelcareers.com
careinnovators is a health care website and networking resource for entrepreneurs, job seekers, investors, and anyone with a desire to improve health care. We profile health start-ups and news that affects them, and also provide free company, event, and funding databases. We organize various panel and networking events to support the health entrepreneurial community. To learn more, visit, http://www.careinnovators.com/
Gene Network Sciences (GNS) is a privately held biotechnology firm based in Cambridge MA, at the leading edge of today's convergence of breakthroughs in genomics and supercomputing. Founded in 2000 to put the power of modern mathematics and computation at the center of the drug discovery and development process, GNS is a uniquely collaborative team of computational physicists, mathematicians, chemists, molecular biologists, bioinformaticians, and software engineers. Through GNS's own discovery efforts and in partnership with many leading innovator health care companies, they are building the future of medicine by revealing the molecular basis of health and disease through the critical biological relationships among genes and proteins, disease progression, and drug efficacy and toxicity. And we are doing this faster than ever thought possible. To learn more, visit, http://www.gnsbiotech.com/